Selpercatinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Healthy
Conditions
Healthy, Renal Insufficiency
Trial Timeline
Dec 19, 2018 → Aug 7, 2019
NCT ID
NCT05469100About Selpercatinib
Selpercatinib is a phase 1 stage product being developed by Eli Lilly for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT05469100. Target conditions include Healthy, Renal Insufficiency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03906331 | Pre-clinical | Completed |
| NCT05324124 | Phase 1 | Completed |
| NCT05136404 | Phase 1 | Completed |
| NCT05089019 | Phase 1 | Completed |
| NCT04280081 | Phase 2 | Active |
| NCT03899792 | Phase 1/2 | Active |
| NCT05338515 | Phase 1 | Completed |
| NCT05469100 | Phase 1 | Completed |
| NCT05436912 | Phase 1 | Completed |
Competing Products
20 competing products in Healthy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 33 |
| Valsartan | Novartis | Phase 1 | 33 |
| CSL112 + Placebo | CSL | Phase 1 | 32 |
| UT-15C | United Therapeutics | Phase 1 | 30 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 25 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 25 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 25 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 25 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 25 |
| TRV734 | Trevena | Phase 1 | 25 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 33 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 28 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 33 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 23 |
| LY2157299 | Eli Lilly | Phase 1 | 33 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 33 |
| LOXO-783 | Eli Lilly | Phase 1 | 33 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 33 |